Chapel Hill, NCNCT03721068Now EnrollingIRB Ready

Neuroblastoma Clinical Trial in Chapel Hill, NC

Access cutting-edge neuroblastoma treatment through this clinical trial at a research site in Chapel Hill. Study-provided care at no cost to qualified participants.

Sponsored by UNC Lineberger Comprehensive Cancer Center

Quick Self-Assessment

See if you qualify for this Chapel Hill location

Preparing your pre-screening questions…

Expert Care in Chapel Hill

Access neuroblastoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related neuroblastoma treatment provided free

Apply for This Chapel Hill Location

Check if you qualify for this neuroblastoma clinical trial in Chapel Hill, NC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chapel Hill

    Convenient for NC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chapel Hill site if eligible
  4. 4Begin participation

About This Neuroblastoma Study in Chapel Hill

The body has different ways of fighting infections and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are molecules that fight infections and protect your body from diseases caused by bacteria and toxic substances. Antibodies work by sticking to those bacteria or substances, which stops them from growing and causing bad effects. T cells are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected. Both antibodies and T cells have been used to treat patients with cancers. They both have shown promise, but neither alone has been enough to cure most patients. This multicenter study is designed to combine both T cells and antibodies in order to create a more effective treatment. The treatment that is being researched is called autologous T lymphocyte chimeric antigen receptor cells (CAR) cells targeted against the disialoganglioside (GD2) antigen that express Interleukin (IL)-15, and the inducible caspase 9 safety switch (iC9), also known as iC9.GD2.CAR.IL-15 T cells.

Sponsor: UNC Lineberger Comprehensive Cancer Center

Who Can Participate

Inclusion Criteria

for the Study:
Written HIPAA authorization signed by legal guardian.
Adequate performance status as defined by Lansky or Karnofsky performance status of ≥ 60 (Lansky for \<16 years of age).
Life expectancy ≥12 weeks.
Histological confirmation of neuroblastoma or ganglioneuroblastoma at initial diagnosis. Bone marrow samples are acceptable as confirmation of neuroblastoma, confirmation of osteosarcoma at diagnosis
High-risk neuroblastoma with persistent/refractory or relapsed disease, defined as:
First or greater relapse of neuroblastoma following completion of aggressive multi-drug frontline therapy.
First episode of progressive neuroblastoma during aggressive multi-drug frontline therapy. Persistent/refractory neuroblastoma as defined by less than a complete response by the revised International Neuroblastoma Response Criteria (INRC) at the conclusion of at least 4 cycles of aggressive multidrug induction chemotherapy on or according to a high-risk neuroblastoma protocol (such as A3973 or ANBL0532).
Patients must be diagnosed with high risk neuroblastoma at initial diagnosis or if non-high risk at time of initial diagnosis must have had evidence of metastatic progression when \>18 months of age as defined in the protocol or relapsed or refractory osteosarcoma that is not responsive to standard treatment.
Measurable or evaluable disease per Revised INRC for subjects with neuroblastoma or measurable disease by Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1 criteria for subjects with osteosarcoma.
Adequate central nervous system function as defined by:
No known Central Nervous System ( CNS) disease
No seizure disorder requiring antiepileptic drug therapy

Exclusion Criteria

for the Study Subjects meeting any of the following exclusion criteria will not be able to participate in this study (procurement, lymphodepletion, and cell infusion).
Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
Has a known additional malignancy that is active and/or progressive requiring treatment.
History of hypersensitivity reactions to murine protein-containing products.
History of hypersensitivity to cyclophosphamide or fludarabine.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chapel Hill?

Yes, this clinical trial (NCT03721068) has an active research site in Chapel Hill, NC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Neuroblastoma Treatment Options in Chapel Hill, NC

If you're searching for neuroblastoma treatment options in Chapel Hill, NC, this clinical trial (NCT03721068) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chapel Hill research site is actively enrolling participants for this clinical trial. You'll receive care from experienced neuroblastoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all neuroblastoma clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Chapel Hill, NC

See all ankylosing spondylitis clinical trials recruiting in Chapel Hill — not just this study.

Browse Ankylosing Spondylitis Trials in Chapel Hill →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsPediatric Cancer TrialsAll Conditions →

Ready to Join in Chapel Hill?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chapel Hill, NC